I would venture a guess that with two more patient
Post# of 145836
If lerolimab is a viable option, for some of the most severe patients, effected by COVID19, I could easily see CytoDyn working with Federal Agencies, to strategically deploy Leronlimab to the front lines of some of the hardest hit areas.
I think it is an exciting time to be an investor of CytoDyn. I also am hopeful that this current pandemic is brought under control in the near term.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)